Boehringer Ingelheim (Canada) Ltd., of Burlington, Ontario, and IBM Canada, of Markham, Ontario, said they plan to explore the use of blockchain technology in clinical trials, which they said marks the first application of the technology in a trial setting in Canada. Details of the transaction and alliance were not disclosed.